Tagged Content

Tags > Medication Updates
Year: Medication:  Abilify (aripiprazole) Addyi Antipsychotics Aripiprazole Aristada Belsomra Brintellix Buprenorphine and naloxone Probuphine Clozapine Chantix and Zyban Cymbalta Daytrana Diazepam Effexor Farxiga Fentanyl and Opioids Geodon Hysingla ER Ingrezza Lunesta Methylphenidate Naloxone/Evzio Naltrexone Olanzapine Olanzapine/Zyprexa Opioids Opioids and Benzodiazepines Rexulti Tanzeum Targiniq ER Tramadol Treatment for Alcohol Use Disorder Vraylar Vynase Ziprasidone Zolpidem Zyprexa General Resources:   DEA Pharmacists' Manual FDA Medication Updates NIMH Mental Health Medications Guide         2017 FDA approves Ingrezza, the first drug to treat tardive dyskinesia Ingrezza (valbenazine) treats tardive dyskinesia, a neurological disorder characterized by repetitive involuntary movements.                 2016 FDA revises risk of mental health side effects of Chantix and Zyban After a large clinical trial, the revised risk of mental health side effects with Chantix (varenicline) and Zyban (bupropion) was found to be lower than previously throught. FDA issues strongest warning of risks when combining opioid pain or cough medicines with benzodiazepines The review found that combined use of these drugs results in serious side effects, including difficulty breathing and death.



View all tags
View RSS XML
The American Psychiatric Nurses Association is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Save 10% on Professional Liability Insurance with CPI
Attend 6 hours of approved Clinical Psychopharmacology Institute sessions to be eligible for a 10% non-cumulative credit to your base professional liability premium through NSO and HPSO.  |  View

2017 Elections Open Now
Cast your vote by July 18 for the APNA Board of Directors and Nominating Committee.  |  View

PCSS-MAT Waiver Training Available Now
Free PCSS-MAT waiver training is now available for nurses and physician assistants.  |  View

Register Now for the APNA 15th Annual Clinical Psychopharmacology Institute
CPI, to be held June 8-11 in Baltimore, Maryland, will offer up to 23 continuing education contact hours in psychopharmacology.  |  View

Free CE of the Month: May 2017
Four sessions are available free of charge to APNA members through May 31st, and two additional sessions are available for Mental Health Month.  |  View

National Patient Safety Goal Related to Suicide: Call for Comments
The Joint Commission is seeking comments on its proposed revisions to the NPSG Related to Suicide for hospitals.  |  View

Take Action: #StandforMentalHealth
Share the new APNA position paper on proactive health care policies to ease the burden of mental illness and substance use disorders.  |  View

 

Tobacco Dependence Resources
Updated expert-vetted online resources from the Tobacco Dependence Branch of the APNA Addictions Council.  |  View

2016 APNA Activity Report Available Now
This report speaks to key APNA activities from the past year. |  View

New Education to Address Opioid Use Crisis
The no cost educational sessions were designed to support nurses in all fields as they address the opioid use epidemic. |  View

New Resources on Violence Prevention
New toolkit and position paper to support psychiatric-mental health nurses in their violence prevention efforts. |  View